Norman Swan

So what are you going to say the next time somebody comes in and says, I've done chat GPT, just say... I'm going to say listen to the episode.

So you're saying that CHAT-GBT is unbiased?

You're such a nice person, much nicer than me.

I know.

You're with the sort of nice and not so nice health report on ABC Radio National.

As you say all the time, Priya, what's a health report without a story on GLP-1s?

You know, the drug of the moment.

And the question is, how much is out there?

It's hard to tell because you can't use government data because a lot of the prescribing, as you know, Priya, are on private scripts, expensive private scripts.

How much is going on?

Well, in fact, there are New South Wales data that help us in this way.

And one of the people who's brought this together is Professor Louisa Jorm, who's Director of the Centre for Big Data Research and Health at the University of New South Wales.

Welcome to the Health Report, Louisa.

Good morning.

Good morning, Norman and Priya.

So let's just start, Louisa, by talking because what we're doing here is talking about really comprehensive data from general practice, which hitherto has not really been available and it's linked to hospital data and very few other states in Australia have it other than New South Wales.

And you've been looking at, well, you literally were looking at semaglutide, but you've been looking at other GLP-1s as well.

And the beauty of this is it observes general practice behaviour, whether it's in the public sector or the private sector, and if you like, whether they're giving a script

on the PBS or a script or a private script, which for obesity is what they have to give.

And on the PBS or private, what was the balance between the two?